Chat with us, powered by LiveChat Have You Read This? Benchmarking In Silico Prediction Of Pharmaceutical Degradation Pathways | Lhasa Limited

Have you read this? Benchmarking In silico prediction of pharmaceutical degradation pathways

We are delighted to share our important new open access article: In silico prediction of pharmaceutical degradation pathways: A benchmarking study using the software program Zeneth. The paper, recently published in Organic Process Research & Development (OPRD) is authored by Lhasa Principal Scientist Rachel Hemingway, alongside industry expert co-authors from AstraZeneca, GSK, Pfizer, BMS, Amgen and Baertschi consulting.

Understanding the chemical stability risks associated with an active pharmaceutical ingredient (API) throughout development is key for drug product quality and safety.

Forced degradation studies (also known as stress testing) are conducted to understand the stability of a drug by:

  • Supporting method development,
  • Validating stability-indicating methods,
  • Identifying potential degradation pathways, and
  • Troubleshooting stability issues.

Information collected on the API and drug product provides a degradation profile which can inform formulation development and packaging needs. This can impact the choice of storage conditions and shelf-life for the final product.

Our software solution, Zeneth considers the reaction conditions that are used in forced degradation studies and is designed to predict theoretical degradation products that can arise for a given API or drug product

In silico assessment using Zeneth can provide knowledge and mechanistic understanding of possible chemical degradation pathways under defined reaction conditions (temperature, pH, water, oxygen, peroxide, light, metal ions, radical initiators); those typically used in forced degradation studies. Excipients (and their known impurities) can also be evaluated against the API to assess API/excipient reactivity risk, using an in-built excipient database.

Read the full paper to discover:

  • How well Zeneth predictions can correctly identify the experimentally observed degradation profiles of 25 APIs from various pharmaceutical portfolios,
  • Two case studies highlighting how prediction data can be utilized to confirm experimental data or assist with identification of unknown degradation products.

This paper explains why using the in silico tool Zeneth is invaluable to your drug development workflow. For more information on how Lhasa can assist with impurity and degradant control, please get in touch.

Last Updated on December 5, 2024 by lhasalimited

You may also like

We’re delighted to share that Lhasa Limited has been shortlisted for the Lush Prize 2026 in the Science category, an award recognising …

Just before the holiday period, our community voted on the most impactful scientific papers of the year authored by industry and regulatory …

We recently had the pleasure of hosting the second Lhasa/IPEC Nitrites in Excipients Collaborative Meeting at our Head Office in Leeds. Following …